This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Infosys Transforms NovaSom's Sleep Apnea Diagnostic Portal To Significantly Speed Test Result Processing

Stocks in this article: INFY

BANGALORE, India and GLEN BURNIE, Maryland, January 14, 2013 /PRNewswire/ --

Cloud-based User Platform Expanded To Support New Offerings

Infosys, a global leader in consulting and technology, has partnered with NovaSom, Inc., the leader in home testing for obstructive sleep apnea (OSA), to significantly improve the efficiency of administering and analyzing results of home tests.

Infosys has designed an innovative cloud-based user portal, Meditrack®, on Salesforce.com to broaden the reach and efficiency of NovaSom's diagnostic solution suite. The new portal provides physicians with a single, easy-to-use interface that speeds up the order-to-delivery of devices, processing of diagnostic data and management of insurance claims.

Meditrack® provides Web interfaces with third-party applications to access and analyze patient data immediately upon wireless receipt of the completed home sleep test. The portal, launched earlier this year, enables NovaSom to shorten the time from test completion to report generation by two days. This capability helps NovaSom's sleep specialist customers deliver faster diagnoses to patients and speed their paths to treatment.

"Patients with OSA are at an increased risk of other chronic diseases. The innovative solution that we developed for NovaSom is helping OSA patients receive faster and better medical care, said Dheeshjith V.G., Senior Vice President and Global Head, Life Sciences at Infosys. "Leveraging our deep medical technology domain knowledge and harnessing the latest technical advancements has allowed us to enable NovaSom to facilitate rapid diagnostic and therapy cycles." 

The NovaSom diagnostic solution also leverages AccuSom®, the first and only FDA-cleared wireless home sleep testing device. With more than 18 million moderate to severe cases of OSA in the United States, NovaSom's suite of accurate, cost-effective home sleep testing solutions is delivering new benefits to patients, health insurers, and specialty and primary care physicians.

In 2012, NovaSom expanded its product suite, launching AccuSom Deliverâ„¢, a customized turnkey solution allowing sleep specialists to incorporate high-quality, at-home sleep testing into their practices on a larger scale. AccuSom Safe Recoveryâ„¢ was also launched this year, which leverages AccuSom's wireless functionality to complete home sleep testing prior to surgery. The new portal from Infosys has helped NovaSom scale operations to meet the expanded solution portfolio more effectively. Sleep specialists, surgeons, and anesthesiologists can now develop a patient management plan that further minimizes the risk of adverse respiratory events and other OSA-related complications during and after surgery.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs